Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient under psychiatric treatment order for violent crime~* More than two violent incidents in the year preceding inclusion, of which at least one within the last three months~* Patient is undergoing psychiatric treatment~* Informed consent~Exclusion Criteria:~* Unable for informed consent~* Intolerance for any prescription compound~* Severe liver failure (Child-Pugh grade c) of renal failure (creatinine clearance \< 15 ml/min.)~* Increased risk of coronary vasospasm: symptoms of vascular disorder (including angina pectoris), history of vascular incidents, severe HBP, ECG-abnormalities in history or at screening prior to inclusion, vascular of cardial souffles.~* History of vascular incidents, hyperlipidaemia, severe HBP, DM~* Use of vasoconstrictive agents such as ergotamine derivates including methysergide, or other triptans.~* Increased risk of serotonergic syndrome: use of irreversible MAO-blocker~* Age \< 18 yr. or \> 65 yr.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): four week double blind placebo treatment phase
- naratriptan (Type: ACTIVE_COMPARATOR): four week double blind experimental treatment using daily naratriptan tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).